Status:
TERMINATED
Ramipril for the Treatment of Oligospermia
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Oligospermia
Teratospermia
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
This is a randomized controlled trial to evaluate the effect of ramipril in stimulating and promoting sperm production in men with low sperm count. Ramipril is an Angiotensin Converting Enzyme Inhibit...
Detailed Description
Approximately half of all infertility problems are caused by male factors. These men account for 17% of patients at the primary health care level that seek help for infertility. Oligospermia (Low sper...
Eligibility Criteria
Inclusion
- Male partner of a couple presenting for infertility.
- Moderate abnormalities of semen parameters (Mean sperm density \<20 million, but ≥ 3 million/ml), and/or motility \< 50%, and/or \< 4% abnormal morphology on at least two separate occasions.
- Age 18-45 years.
- Normal renal function defined as Glomerular filtration rate \> 90
Exclusion
- Patients that are currently taking thiazide, cyclosporin, lithium, and allopurinol or the use of these medications in the last 2 weeks.
- The frequent use of NSAIDS (3 or more times a week).
- Vasectomy reversal.
- Regular use of tobacco products.
- Mean white blood cell count \>1 million/ml in the ejaculate.
- Inability or unwillingness to participate in evaluations required by the study.
- Potassium \> 5.0.
- Systolic blood pressure \< 90 mmHg.
- Currently use of ACEI
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01856361
Start Date
July 1 2013
End Date
June 1 2016
Last Update
June 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College, Department of Urology
New York, New York, United States, 10065